In this article, we will take a look at the 5 most promising gene editing stocks according to analysts. To see more such companies, go directly to 11 Most Promising Gene Editing Stocks According to Analysts.
5. Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Number of Hedge Fund Holders: 25
One-Year Average Price Target: $12.13
Pacific Biosciences of California, Inc. (NASDAQ:PACB) provides key technologies related to RNA Sequencing, Epigenetics, Target Sequencing, Whole Genome Sequencing and more. In February, Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its fourth quarter results. Adjusted EPS in the period came in at -$0.35, beating estimates by $0.02. Revenue in the period fell about 24% on a YoY basis to reach $0.06 million. Pacific Biosciences of California, Inc. (NASDAQ:PACB) said that it received record orders in the fourth quarter.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is gaining the spotlight after revealing its new long-read sequencer, known as Revio. Revio is the first sequencer to use Nvidia’s (NVDA) GPUs and the throughput of its new SMRT cell is 15 times higher than the Sequel II.
As of the end of the fourth quarter of 2022, 25 hedge funds out of the 943 funds tracked by Insider Monkey reported having stakes in Pacific Biosciences of California, Inc. (NASDAQ:PACB). The net worth of these stakes at the end of the period was about $384 million. Like PACB, Intellia Therapeutics Inc (NASDAQ:NTLA), Crispr Therapeutics AG (NASDAQ:CRSP) and Editas Medicine Inc (NASDAQ:EDIT) are some of the most promising gene editing stocks.
4. CRISPR Therapeutics AG (NASDAQ:CRSP)
Number of Hedge Fund Holders: 28
One-Year Average Price Target: $89.57
CRISPR Therapeutics AG (NASDAQ:CRSP) is perhaps the most popular gene editing company in the world. CRISPR Therapeutics AG (NASDAQ:CRSP) has a huge pipeline of treatments that use genome editing and sequencing to treat several diseases. As of March 6, CRISPR Therapeutics AG (NASDAQ:CRSP) is hovering around $49. CRISPR Therapeutics AG (NASDAQ:CRSP)’s average analyst price target stands at $89, which shows that the shares of CRISPR have a strong upside potential from the current levels.
CRISPR Therapeutics AG (NASDAQ:CRSP) shares jumped in February after the company posted Q4 results. CRISPR Therapeutics AG (NASDAQ:CRSP) discussed the regulatory prospects for its gene-edited therapy exa-cel co-developed with Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).
3. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Number of Hedge Fund Holders: 31
One-Year Average Price Target: $48.44
Biotechnology company Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a making a promising foray into the world of gene editing. Last year, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) entered into a partnership with gene editing company Metagenomi. The companies said that they will join hands to conduct research aimed initially at delivering investigational medicines for up to four genetic targets.
In December 2022, Morgan Stanley started covering Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) with an Equal Weight rating. Morgan Stanley said it expects a competitive launch for eplontersen in 2023 and that the treatment of the company will be the second drug to market for transthyretin amyloid polyneuropathy (ATTR-PN) after Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Amvuttra (patisiran).
In January, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) revealed that the FDA granted the Fast Track designation for its investigational therapy olezarsen for familial chylomicronemia syndrome (FCS), a rare form of dyslipidemia.
2. Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Number of Hedge Fund Holders: 39
One-Year Average Price Target: $96.28
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the most notable gene editing companies working on CRISPR-based technologies.
Earlier this month, the US FDA cleared Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s application seeking to start a trial of CRISPR-based gene editing therapy NTLA-2002 in the U.S. to treat hereditary angioedema (HAE).
At the end of the fourth quarter of 2022, 39 hedge funds out of the 943 funds tracked by Insider Monkey reported owning stakes in Intellia Therapeutics, Inc. (NASDAQ:NTLA). The total value of these stakes at the end of the quarter was $690 million. The biggest stakeholder of Intellia Therapeutics, Inc. (NASDAQ:NTLA) was ARK Investment Management which had a $328 million stake in the company.
1. Exact Sciences Corporation (NASDAQ:EXAS)
Number of Hedge Fund Holders: 39
One-Year Average Price Target: $73.65
Exact Sciences Corporation (NASDAQ:EXAS) is one of the most notable and promising stocks in the genomics space. Exact Sciences Corporation (NASDAQ:EXAS) is offering several solutions in related industries. The oncology-focused company is known for its The Oncotype DX® tests which deliver relevant genomic intelligence specific to the individual biology of a patient’s tumor. Back in 2019, Exact Sciences Corporation (NASDAQ:EXAS) completed its $2.8 billion acquisition of genomic diagnostics maker Genomic Health.
You can also take a peek at 15 Best Short-Term Stocks to Buy and 10 Best Stocks to Buy for High Returns.
